Business Description
Percheron Therapeutics is an Australian biotech company focused on developing new treatments for cancer and rare diseases. Its main drug candidate, ATL1102, is currently in advanced clinical trials for Duchenne muscular dystrophy, multiple sclerosis, and asthma, while a second therapy, HMBD-002, has completed early-stage trials targeting certain immune and cancer cells. Founded in 2000 and based in Melbourne, the company was previously called Antisense Therapeutics before adopting its current name in late 2023.
